ABSTRACT Acid acetone extracts of caudate nucleus from bovine brain were found to contain an amidated opioid octapeptide with the following structure: Tyr-Gly-Gly-Phe-Met-Arg-ArgVal-NH2. The peptide has been named metorphamide. Bovine metorphamide appears to be derived by proteolytic cleavage from proenkephalin, the common precursor to [Met5]enkephalin and [Leu5]enkephalin. The cleavage within the precursor giving rise to the carboxyl terminus of metorphamide occurs at a single arginine residue and is followed by transformation of a carboxyl-terminal glycine into an amide group. Metorphamide was detected in bovine caudate nucleus extracts by radioimmunoassay, and it was purified to homogeneity by gel filtration and reversed-phase high performance liquid chromatography. Amino acid composition analysis and automated Edman degradation in the gas-phase sequencer confirmed the postulated amino acid sequence. Carboxyl-terminal amidation of bovine metorphamide was shown by stability to carboxypeptidase A digestion and full crossreactivity in a radioimmunoassay that required the carboxyl-terminal amide as part of the recognition site. A synthetic replicate of metorphamide as well as several synthetic analogs were tested for opioid activity in several bioassays and binding assays, and metorphamide was found to have a high p-binding activity. Metorphamide is the only known naturally occurring opioid peptide that has a high pbindingactivity. The K-bindingactivity is w5O% that of the p-binding activity, but 8-binding activity is negligible.
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Recent studies have begun to yield information on the posttranslational proteolytic processing of opioid peptide precursors in brain. Most work has been done on prodynorphin (1) , in which processing appears to be unusual because the carboxyl termini of both dynorphin A1_8 (2) (3) (4) and dynorphin B (rimorphin) (5) (6) (7) are released from the precursor by cleavage at single arginine residues rather than at the classical processing sites, paired basic residues (8) . However, cleavages at paired basic amino acids (lysyl-arginyl) release the vital amino-terminal sequence of all the opioids in prodynorphin and also the carboxyl termini of a-neo-endorphin (9) and dynorphin A (10) .
To examine whether proenkephalin (11) (12) (13) , the second major opioid peptide precursor, also gives rise to opioids that are generated by single arginine cleavage mechanisms, we have examined brain tissue for the presence of such cleavage products. We postulated that an amidated fragment of proenkephalin could occur naturally, if indeed cleavage at single arginine would occur (Fig. 1) . Here we show that acid acetone extracts from bovine caudate nucleus contain a peptide that crossreacts with antibodies generated against this synthetic fragment of proenkephalin. The immunoreactive peptide was purified to homoTyr-G ly-G ly-P he-Leu-Arg-Arg-I I e dynorphin A (1-8) geneity and chemically characterized, and its primary structure was shown to be identical to the postulated cleavage product.
The biologic activity of a synthetic replicate of the peptide was characterized in a number of opioid bioassays and binding as-
says. MATERIALS AND METHODS
Synthetic Peptides, Preparation of Antiserum, and Radioimmunoassay. Peptides were synthesized by the solid-phase method of Merrifield (14) on hydroxymethyl resin substituted with the desired carboxyl-terminal amino acid (-0.5 mmol/g). Metorphamide (amidated carboxyl terminus) was synthesized on p-methylbenzhydrylamine resin (0.5 mmol/g) (15) . After synthesis, resins were treated with hydrogen fluoride and cleaved peptides were purified by partition chromatography on Sephadex G-25. The purified peptides were shown to be pure by thin layer chromatography and reversed-phase HPLC. Amino acid analysis confirmed the correct composition of the peptides.
An antiserum to synthetic metorphamide was generated in a male New Zealand White rabbit by injecting synthetic peptide linked to bovine thyroglobulin by carbodiimide as described (16) . The resulting antiserum (R1-3) was used in a radioimmunoassay (RIA) with "2I-labeled synthetic metorphamide as a tracer. The RIA procedure was as described (16) with modifications (2 Residual organic solvent was evaporated from the aqueous layer under a stream of nitrogen for 16 hr. The extract (-150 ml) was neutralized with ammonia and spun at 15,000 X g for 20 min. The supernatant was acidified with glacial acetic acid to a final concentration of 5%, spun at 15,000 x g for 20 min, and adsorbed to preparative reversed-phase C-18 resin (Alltech Associates, Deerfield, IL; particle size, 25 Am) equilibrated with 5% acetic acid in a 1.9 x 7cm glass column. After washing with 5% acetic acid, adsorbed peptides were eluted with acid acetone (acetone/water/12 M HCI; 40:6:1). Fractions containing peptide material were evaporated with nitrogen and chromatographed on Sephadex G-50 in 50% acetic acid in a 2.5 x 120 cm column. Immunoreactive fractions were evaporated with nitrogen, taken up in 5% acetic acid, combined, and subjected to two successive reversed-phase HPLC separation systems on an Altex (Berkeley, CA) Ultrasphere octadecasilica (ODS) column (250 x 4.6 mm; particle size, 5 pum). The two HPLC systems were as follows: 50 mM NaH2PO4/phosphoric acid (1 ml/ liter)/5% methanol/acetonitrile, pH 2.7; and 100 mM Na2HPO4/ 5% methanol/acetonitrile, pH 7.0. Peptides were eluted with an acetonitrile gradient as shown in Fig. 2 . Purified metorphamide was then desalted on an Altex Ultrasphere ODS column (75 x 4.6 mm; particle size, 3 Am) with the following acetonitrile gradient in 0.1% trifluoroacetic acid: 0-15% in 5 min, 15 -50% in 55 min. Flow rate was 1.25 ml/min in all HPLC steps. Amino acid analyses and gas-phase sequence determinations were carried out as described (19, 20 [12] [13] [14] [15] pmol/g of tissue. In the Sephadex G-50 gel-filtration chromatography step that was included in the purification scheme, the bovine metorphamide-immunoreactive material eluted at the same position as "2I-labeled synthetic metorphamide, which suggests that the molecular size of bovine metorphamide is similar to that.of synthetic metorphamide. No higher molecular weight components reacting with the metorphamide antibodies were observed in the fractions eluting from this column (data not shown). Fig. 2 shows the optical density and immunoreactivity profiles of a typical second reversed-phase HPLC step in the purification of bovine metorphamide. The peptide eluted as a single symmetrical absorbance peak that coincided with the immunoreactivity in the metorphamide RIA. The metorphamidecontaining peak from the second reversed-phase HPLC step was desalted and chemically characterized by amino acid composition analysis and automated Edman degradation in the gasphase sequencer. Sequence determination gave unambiguous results for the first seven amino acid residues (Table 1) . Amino acid composition analysis showed the presence of eight amino acid residues, seven of which were identified during the automated Edman degradation (Table 2 ). The additional amino acid, valine, could thus be assigned to the carboxyl terminus. Neurobiology: Weber et al. Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-NH2. The sequence of the first seven amino acids was determined by automated Edman degradation in the gas-phase sequencer. The carboxyl-terminal valine was assigned from amino acid analysis data ( Table 2 ). Carboxyl-terminal amidation was shown by stability to carboxypeptidase A digestion (Fig. 3) and by full crossreactivity of bovine metorphamide in a RIA requiring the carboxyl-terminal amide as part ofthe recognition site. >PhNCS, phenylthiohydantoin.
Based on the biosynthetic origin of metorphamide as part of the proenkephalin precursor molecule (11-13) and the putative cleavage and processing events that would lead to its formation, we postulated that metorphamide should have an amidated carboxyl terminus (Fig. 1) . This prediction was confirmed by the immunological characteristics of the peptide as well as by carboxypeptidase A digestion experiments. Fig. 3 shows that bovine metorphamide was completely stable to carboxypeptidase A action. In contrast, synthetic dynorphin18 that was added together with bovine metorphamide to the enzyme solution was completely destroyed after incubation at 37TC for 5 min. In addition, bovine metorphamide had full crossreactivity as compared to synthetic metorphamide in the metorphamide RIA that required the carboxyl-terminal amide as part of the recognition site (see Materials and Methods). It was, therefore, concluded that bovine metorphamide is amidated at the carboxyl terminus and that the complete primary structure of the peptide is TyrGly-Gly-Phe-Met-Arg-Arg-Val-NH2.
Biologic Activity of Metorphamide and Its Analogs. In pharmacological assays (Table 3) , the most striking effect of extending [Met5]enkephalin at the carboxyl terminus is the increase in activity in the rabbit vas deferens. On the other hand, there is an almost complete loss of activity in the rat vas deferens. In the myenteric plexus and mouse vas deferens the carboxyl terminally extended -Arg6, -Arg6-Arg7, -Arg6-Arg7-Val8 peptides are nearly equiactive; in contrast, -Arg6-Arge-Val8-NH2
(metorphamide; the amide of the octapeptide) is more active in the myenteric plexus than in the mouse vas deferens.
In the binding assays, any extension of the peptide beyond the pentapeptide abolishes 8-selectivity (Table 4 ). The addition of arginine-6 introduces some affinity at the K-site. Addition of Arg6-Arg7 leads to a marked increase in affinity at all three sites but especially at the K-site as shown for dynorphin Al13 (23), dynorphin A1_7 and the extensions at the carboxyl terminus of dynorphin A1.7 (22) . Extension at the carboxyl terminus by Arg6-Arg7-Val8 increases affinity at the u-and K-sites but not at the 8-site. Amidation of valine-8 (metorphamide) causes an increase in K-affinity with little change at the two other sites. Thus, at Kd concentrations of the 3H-labeled ligands metorphamide is a potent agonist, having a potency (Ki) of 0.12 nM at the ,Isite and binding ratios of Ki for ,u/Kl for 8 of 0.04 and of Ki for .u/Ki for K of 0.46, whereas the respective values for the nonamidated peptide are 0.29 nM, 0.07, and 0.14.
DISCUSSION
We have shown that the amidated opioid octapeptide that we have characterized here occurs in significant quantities (12) (13) (14) (15) pmol/g of tissue) in acid acetone extracts of bovine caudate nucleus. The amounts were sufficient to allow purification to homogeneity and, with the aid of microsequence analysis and high sensitivity amino acid analysis techniques, the unambiguous chemical characterization of the peptide. According to its structural characteristics, the natural peptide has been named metorphamide ([Met5]enkephalin containing endorphin with carboxyl-terminal amide). In preliminary studies, we found that metorphamide immunoreactive material is present in acid aceAliquots of42 pmol ofbovine metorphamide were hydrolyzed. Values are not corrected for hydrolysis losses and represent mean of two analyses. Cys was determined as cysteic acid.
Proc. Nati. Acad. Sci. USA 80 (1983) (24) , and an opioid octapeptide, [Met5]enkephalyl-Arg6-Gly7-Leu8 (25) . Both [Met5]-and [Leu5]enkephalin and the hepta-and octapeptide opioids are generated from proenkephalin by proteolytic cleavage at double basic amino acid residues, which are primary cleavage sites for proteolytic processing of peptide hormone precursors (8) . In contrast, metorphamide is apparently generated by a proteolytic processing mechanism that involves cleavage at a single arginine residue (Fig. 1) . It (27) , the carboxyl-terminal octapeptide of cholecystokinin (28), somatostatin-28 (29) , two fragments of gastrin-releasing peptide (30) , and growth hormone-releasing factor (31) are also generated from their respective precursors by single arginine cleavages. These previous findings together with the findings reported here suggest that the single arginine cleavage is an (32, 33) .
The presence of metorphamide in the caudate nucleus of bovine brain is of particular interest in that it is the only naturally occurring opioid peptide that has a particularly high affinity for the ,u-binding site, a somewhat lesser affinity for the K-binding site, and a very low affinity for the 8- (34) .
